Cargando…
Optimal tolerability and high efficacy of a modified schedule of lapatinib–capecitabine in advanced breast cancer patients
PURPOSE: Diarrhea in relation to the lapatinib–capecitabine regimen is a common and debilitating side effect which may interfere with optimal treatment delivery. We performed a post hoc analysis in human epidermal growth factor receptor 2-positive advanced breast cancer patients treated with a modif...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895217/ https://www.ncbi.nlm.nih.gov/pubmed/24292401 http://dx.doi.org/10.1007/s00432-013-1556-4 |
_version_ | 1782299944201224192 |
---|---|
author | Gamucci, T. Moscetti, L. Mentuccia, L. Pizzuti, L. Mauri, M. Zampa, G. Pavese, I. Sperduti, I. Vaccaro, A. Vici, P. |
author_facet | Gamucci, T. Moscetti, L. Mentuccia, L. Pizzuti, L. Mauri, M. Zampa, G. Pavese, I. Sperduti, I. Vaccaro, A. Vici, P. |
author_sort | Gamucci, T. |
collection | PubMed |
description | PURPOSE: Diarrhea in relation to the lapatinib–capecitabine regimen is a common and debilitating side effect which may interfere with optimal treatment delivery. We performed a post hoc analysis in human epidermal growth factor receptor 2-positive advanced breast cancer patients treated with a modified schedule in its administration, aimed primarily to evaluate grade (G) ≥2 diarrhea incidence and, secondarily, treatment efficacy. PATIENTS AND METHODS: Treatment schedule consisted of lapatinib 1,250 mg daily for the first 10 days, then in combination with capecitabine, 2,000 mg/m(2), starting day 11 for the first cycle, and thereafter from day 8, for 14 days of a 21-day cycle, in 3 daily administrations. Lapatinib was dissolved in water, and cholestyramine was continuously given twice a day. RESULTS: Among 38 patients treated and analyzed, the incidence of G ≥ 2 diarrhea was 13.2 %. In 28 patients diarrhea was not observed, while G1–2 diarrhea was reported in 9 (23.7 %) patients; a single episode of G3 diarrhea was observed in 1 (2.6 %) patient. Overall response rate was 34.2 %, clinical benefit 55.3 %, and median progression-free survival 10 months. CONCLUSION: The results of the present post hoc analysis are very encouraging, both in terms of tolerability and treatment efficacy, and all data compare favorably with previous reports of “conventional” administration of the lapatinib–capecitabine regimen. |
format | Online Article Text |
id | pubmed-3895217 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-38952172014-01-22 Optimal tolerability and high efficacy of a modified schedule of lapatinib–capecitabine in advanced breast cancer patients Gamucci, T. Moscetti, L. Mentuccia, L. Pizzuti, L. Mauri, M. Zampa, G. Pavese, I. Sperduti, I. Vaccaro, A. Vici, P. J Cancer Res Clin Oncol Original Paper PURPOSE: Diarrhea in relation to the lapatinib–capecitabine regimen is a common and debilitating side effect which may interfere with optimal treatment delivery. We performed a post hoc analysis in human epidermal growth factor receptor 2-positive advanced breast cancer patients treated with a modified schedule in its administration, aimed primarily to evaluate grade (G) ≥2 diarrhea incidence and, secondarily, treatment efficacy. PATIENTS AND METHODS: Treatment schedule consisted of lapatinib 1,250 mg daily for the first 10 days, then in combination with capecitabine, 2,000 mg/m(2), starting day 11 for the first cycle, and thereafter from day 8, for 14 days of a 21-day cycle, in 3 daily administrations. Lapatinib was dissolved in water, and cholestyramine was continuously given twice a day. RESULTS: Among 38 patients treated and analyzed, the incidence of G ≥ 2 diarrhea was 13.2 %. In 28 patients diarrhea was not observed, while G1–2 diarrhea was reported in 9 (23.7 %) patients; a single episode of G3 diarrhea was observed in 1 (2.6 %) patient. Overall response rate was 34.2 %, clinical benefit 55.3 %, and median progression-free survival 10 months. CONCLUSION: The results of the present post hoc analysis are very encouraging, both in terms of tolerability and treatment efficacy, and all data compare favorably with previous reports of “conventional” administration of the lapatinib–capecitabine regimen. Springer Berlin Heidelberg 2013-11-29 2014 /pmc/articles/PMC3895217/ /pubmed/24292401 http://dx.doi.org/10.1007/s00432-013-1556-4 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by/2.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Paper Gamucci, T. Moscetti, L. Mentuccia, L. Pizzuti, L. Mauri, M. Zampa, G. Pavese, I. Sperduti, I. Vaccaro, A. Vici, P. Optimal tolerability and high efficacy of a modified schedule of lapatinib–capecitabine in advanced breast cancer patients |
title | Optimal tolerability and high efficacy of a modified schedule of lapatinib–capecitabine in advanced breast cancer patients |
title_full | Optimal tolerability and high efficacy of a modified schedule of lapatinib–capecitabine in advanced breast cancer patients |
title_fullStr | Optimal tolerability and high efficacy of a modified schedule of lapatinib–capecitabine in advanced breast cancer patients |
title_full_unstemmed | Optimal tolerability and high efficacy of a modified schedule of lapatinib–capecitabine in advanced breast cancer patients |
title_short | Optimal tolerability and high efficacy of a modified schedule of lapatinib–capecitabine in advanced breast cancer patients |
title_sort | optimal tolerability and high efficacy of a modified schedule of lapatinib–capecitabine in advanced breast cancer patients |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895217/ https://www.ncbi.nlm.nih.gov/pubmed/24292401 http://dx.doi.org/10.1007/s00432-013-1556-4 |
work_keys_str_mv | AT gamuccit optimaltolerabilityandhighefficacyofamodifiedscheduleoflapatinibcapecitabineinadvancedbreastcancerpatients AT moscettil optimaltolerabilityandhighefficacyofamodifiedscheduleoflapatinibcapecitabineinadvancedbreastcancerpatients AT mentuccial optimaltolerabilityandhighefficacyofamodifiedscheduleoflapatinibcapecitabineinadvancedbreastcancerpatients AT pizzutil optimaltolerabilityandhighefficacyofamodifiedscheduleoflapatinibcapecitabineinadvancedbreastcancerpatients AT maurim optimaltolerabilityandhighefficacyofamodifiedscheduleoflapatinibcapecitabineinadvancedbreastcancerpatients AT zampag optimaltolerabilityandhighefficacyofamodifiedscheduleoflapatinibcapecitabineinadvancedbreastcancerpatients AT pavesei optimaltolerabilityandhighefficacyofamodifiedscheduleoflapatinibcapecitabineinadvancedbreastcancerpatients AT sperdutii optimaltolerabilityandhighefficacyofamodifiedscheduleoflapatinibcapecitabineinadvancedbreastcancerpatients AT vaccaroa optimaltolerabilityandhighefficacyofamodifiedscheduleoflapatinibcapecitabineinadvancedbreastcancerpatients AT vicip optimaltolerabilityandhighefficacyofamodifiedscheduleoflapatinibcapecitabineinadvancedbreastcancerpatients |